Time course of adverse reactions following BNT162b2 vaccination in healthy and allergic disease individuals aged 5–11 years and comparison with individuals aged 12–15 years: an observational and historical cohort study

Makoto Yoshida, Yurie Kobashi, Yuzo Shimazu, Hiroaki Saito, Chika Yamamoto, Takeshi Kawamura, Masatoshi Wakui, Kenzo Takahashi, Naomi Ito, Yoshitaka Nishikawa, Tianchen Zhao, Masaharu Tsubokura

Research output: Contribution to journalArticlepeer-review

Abstract

We aimed to investigate the type and frequency of adverse events over 7 days following the first and second BNT162b2 vaccination. This observational and historical cohort study included patients aged 5–11 years who received two doses of BNT162b2 and provided consent along with their guardians. We collected data on sex, age, height, weight, blood type, history of Bacille Calmette-Guerin vaccination, allergic disease, medication, history of coronavirus disease 2019 (COVID-19), and adverse reactions 7 days following the first and second BNT162b2 vaccination using a questionnaire. Our results were compared with previously reported results for individuals aged 12–15 years. A total of 421 participants were eligible for this study. Among the 216 patients with allergic disease, 48 (22.2%) had experienced worsening of their chronic diseases, and the frequency of fatigue and dizziness after the second dose was higher than that of healthy individuals. The experience of systemic adverse reactions was associated with asthma. The frequency of headache, diarrhea, fatigue, muscle/joint pain, and fever after the second BNT162b2 vaccination was lower in individuals aged 5–11 years than in those aged 12–15 years. Fever was the only systemic adverse reaction that lasted longer than 5 days (1.0% of participants). Conclusions: Individuals with allergic diseases, who are potentially susceptible to COVID-19, may experience worsening of their chronic diseases and more frequent adverse reactions after BNT162b2 vaccination than healthy individuals. To ensure that children with allergic diseases receive the vaccine safely, further information needs to be collected.What is Known:• Adverse reactions afterBNT162b2 vaccination among individuals aged 5–11 years are generallynonserious, more common after second vaccination, and substantially less commoncompared to those observed among individuals aged 12–15 years.What is New:• Individuals with allergic diseasesexperienced worsening of their chronic diseases and more frequent adversereactions after BNT162b2 vaccination than healthy individuals.• Systemic adverse reactions were associatedwith asthma. Fever was the only systemic adversereaction that lasted longer than 5 days.

Original languageEnglish
Pages (from-to)123-133
Number of pages11
JournalEuropean Journal of Pediatrics
Volume182
Issue number1
DOIs
Publication statusPublished - 2023 Jan

Keywords

  • Adverse reactions
  • Allergy
  • Asthma
  • BNT162b2
  • Children
  • Coronavirus disease 2019

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Fingerprint

Dive into the research topics of 'Time course of adverse reactions following BNT162b2 vaccination in healthy and allergic disease individuals aged 5–11 years and comparison with individuals aged 12–15 years: an observational and historical cohort study'. Together they form a unique fingerprint.

Cite this